Drug Profile
Danicamtiv - MyoKardia
Alternative Names: BMS-986434; MYK 491; SAR 440181Latest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator MyoKardia
- Developer MyoKardia; Sanofi
- Class Amides; Cardiovascular therapies; Fluorinated hydrocarbons; Isoxazoles; Organic sulfur compounds; Piperidines; Pyrazoles; Small molecules
- Mechanism of Action Cardiac myosin stimulants; Genetic process modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dilated cardiomyopathy
Most Recent Events
- 10 Nov 2023 Bristol-Myers Squibb completes the phase I pharmacokinetics trial (In Volunteers) in USA (NCT06027437)
- 07 Sep 2023 Bristol-Myers Squibb plans a phase I trial (In volunteers) in September 2023 (NCT06027437)
- 05 Sep 2023 Bristol Myers Squibb initiates a phase I pharmacokinetics trial (In Volunteers) in USA (NCT06027437)